• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Supprelin LA (histrelin acetate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Supprelin LA (histrelin acetate)

  • Profile

Profile

Contact Information

Contact: Endo International
Website: http://www.supprelinla.com/

Currently Enrolling Trials

    Show More

    General Information

    Supprelin LA is a GnRH agonist and an inhibitor of gonadotropin secretion when given continuously. It desensitizes responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in ovarian and testicular steroidogenesis.

    Supprelin LA is specifically indicated for the treatment of children with central precocious puberty (CPP).

    Mechanism of Action

    Supprelin LA is a GnRH agonist and an inhibitor of gonadotropin secretion when given continuously. It delivers approximately 65 mcg histrelin acetate per day. Following an initial stimulatory phase, chronic, subcutaneous administration of histrelin acetate desensitizes responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in ovarian and testicular steroidogenesis. Administration of histrelin acetate results in an initial increase in circulating levels of LH and FSH, leading to a transient increase in concentration of gonadal steroids (testosterone and dihydrotestosterone in males, estrone and estradiol in premenopausal females). However, continuous administration of histrelin acetate causes a reversible down-regulation of the GnRH receptors in the pituitary gland and desensitization of the pituitary gonadotropes. These inhibitory effects result in decreased levels of LH and FSH.

    Side Effects

    Adverse events associated with the use of Supprelin LA may include, but are not limited to, the following:

    • implant site reaction
    • keloid scar
    • scar
    • suture related complication
    • application site pain
    • post procedural pain

    Dosing/Administration

    Supprelin LA is supplied as an implant for continuous release over the course of 12 months. The recommended initial dose of the drug is one implant every 12 months.

    Clinical Trial Results

    FDA Approval
    FDA approval of Supprelin LA is based on the results of two open-label, single-arm clinical studies. Study 1 enrolled 11 pretreated female subjects, 3.7 to 11.0 years of age. Study 2 enrolled 36 subjects (33 females and 3 males), 4.5 to 11.6 years of age. Sixteen of these subjects were pretreated and 20 were treatment-naīve. Endpoints were similar in both trials and included measurements of the suppression of gonadotropins (luteinizing hormone and follicle stimulating hormone) and gonadal sex steroids (estrogen in girls and testosterone in boys, respectively). Additional assessments were clinical (evidence of stabilization or regression of signs of puberty) or gonadal steroid-dependent (bone age, linear growth). In study 2 the primary measure of efficacy was LH suppression (defined as a peak LH <4 mIU/mL following stimulation with the GnRH analog leuprolide acetate). In both trials the endpoints were achieved. In study 2, suppression of LH was induced in all treatment naīve subjects and maintained in all pretreated subjects one month after implantation and continued through month 12. Secondary efficacy assessments indicated stabilization of disease. In addition, in study 2 estradiol suppression was present in 100% of the females through month 9 and 97% at month 12. Testosterone suppression was maintained in the three pre-treated males.

    Approval Date: 2007-05-01
    Company Name: Indevus Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing